Neutralizing and cross-neutralizing antibody titres induced by bivalent and quadrivalent human papillomavirus vaccines in the target population of organized vaccination programmes

Barzon, Luisa; Shaughnessy, Laura; Masiero, S.; Pacenti, Monia; Marcati, Giorgia; Mantelli, Barbara; Gabrielli, Liliana; Pascucci, Maria Grazia; Lazzarotto, Tiziana; Caputo, Antonella; Palù, Giorgio

doi:10.1016/j.vaccine.2014.07.014

Cited by 27 publications

(30 citation statements)

References 36 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…the titres of 17-year-olds vaccinated at the age of 12 years are higher than those 17-year-olds vaccinated at the age of 15 years) [45][46][47][48]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54]. (4) 2vHPV, due presumably to its adjuvant, induces greater antibody titres vs. HPV16 and HPV18 and invokes higher titres of cross-protective antibodies against untargeted HPV genotypes than 4vHPV [50][51][52][53][54].…”

Section: Humoral Immune Responsesmentioning

confidence: 99%

“…The FDA approval of 9vHPV was based primarily on data from five clinical trials, including a randomized clinical trial in approximately 14 000 women aged 16-26 years comparing 9vHPV to 4vHPV [106]. Key findings for 9vHPV vs. 4vHPV included: (1) 97% reduction in the combined incidence of high-grade cervical, vulvar, and vaginal disease caused by HPV types 31, 33, 45, 52, and 58; (2) noninferior seroconversion and geometric mean antibody titres for HPV6, 11, 16, and 18; (3) numerically higher rates of injection site reactions; and (4) immunobridging studies of 9-to 15-year-old adolescent girls and boys showed non-inferior seroconversion and geometric mean antibody titres for all nine HPV types (6,11,16,18,31,33,45,52,58), compared to 16-to 26-year-old women [105]. Long-term follow-up studies are ongoing to access immunogenicity, effectiveness, and safety of 9vHPV.…”

Section: Second Generation: Nonavalentmentioning

confidence: 99%

See 1 more Smart Citation

Prophylactic HPV vaccination: past, present, and future

Castle

Maza²

2015

Epidemiol. Infect.

156

114

View full text Add to dashboard Cite

Human papillomavirus (HPV) is the necessary cause of cervical cancer, the fourth most common cancer and cause of cancer-related death in females worldwide. HPV also causes anal, vaginal, vulvar, penile, and oropharyngeal cancer. Prophylactic HPV vaccines based on recombinantly expressed virus-like particles have been developed. Two first-generation, U.S. Food and Drug Administration (FDA)-approved vaccines prevent infections and disease caused by HPV16 and HPV18, the two HPV genotypes that cause approximately 70% of cervical cancer, and one of these vaccines also prevents HPV6 and HPV11, the two HPV genotypes that cause 90% of genital warts. A next-generation vaccine, recently approved by the U.S. FDA, targets HPV16, HPV18, and five additional HPV genotypes that together causes approximately 90% of cervical cancer as well as HPV6 and HPV11. In clinical trials, these vaccines have shown high levels of efficacy against disease and infections caused by the targeted HPV genotypes in adolescent females and males and older females. Data indicate population effectiveness, and therefore cost effectiveness, is highest in HPV-naive young females prior to becoming sexually active. Countries that implemented HPV vaccination before 2010 have already experienced decreases in population prevalence of targeted HPV genotypes and related anogenital diseases in women and via herd protection in heterosexual men. Importantly, after more than 100 million doses given worldwide, HPV vaccination has demonstrated an excellent safety profile. With demonstrated efficacy, cost-effectiveness, and safety, universal HPV vaccination of all young, adolescent women, and with available resources at least high-risk groups of men, should be a global health priority. Failure to do so will result in millions of women dying from avertable cervical cancers, especially in low- and middle-income countries, and many thousands of women and men dying from other HPV-related cancers.

show abstract

Section: Humoral Immune Responsesmentioning

confidence: 99%

Section: Second Generation: Nonavalentmentioning

confidence: 99%

Prophylactic HPV vaccination: past, present, and future

Castle

Maza²

2015

Epidemiol. Infect.

156

114

View full text Add to dashboard Cite

show abstract

“…Another study showed that the bivalent vaccine had greater efficacy than the quadrivalent vaccine against persistent infection with HPV31 and HPV45 . Also, it was reported the bivalent vaccine induced higher titer of HPV31 and HPV45 cross‐neutralizing antibodies than the quadrivalent vaccine . However, follow‐up studies suggested that these antibodies may decrease over time .…”

Section: Discussionmentioning

confidence: 99%

Prevalence of Human Papillomavirus infection among Chilean women from 2012 to 2016

Vergara

Espinoza²,

Balanda

et al. 2017

Journal of Medical Virology

View full text Add to dashboard Cite

Here, we evaluated the prevalence of Human Papillomavirus (HPV) in two groups of Chilean women. The first group consisted of 3235 women aged 18-64 years attended in six primary care centers of Santiago. The second group consisted of 456 women 18-85 aged who consulted the Gynaecology Department of the Reference Hospital of Santiago. Samples were collected from October 2012 to February 2016. Cervical swabs were analyzed both HPV genotyping by PCR and Reverse Line Blot, and cervical cytology by Pap testing. Results showed a prevalence of 12.0% HPV positive, 10.3% high-risk (HR) HPV types positive, 3.9% low-risk (LR) HPV types positive, and 1.0% Pap positive in group 1. The most frequent types were 16, 66, and 59, with a prevalence of 3.0%, 1.6%, and 1.5%, respectively. The prevalence were 71.9% HPV positive, 67.3% HR-HPV types positive, 13.6% LR-HPV types positive, and 62.5% Pap positive in group 2. The most frequent types were 16, 31, and 58, with prevalence of 33.6%, 10.5%, and 7.0%, respectively. Among infected women with HPV: 7.6% were infected with HPV16 or HPV18, 3.0% with HPV31, HPV33 or HPV45, and 6.7% with any other HR-HPV. These findings show great difference in HPV prevalence and types between primary care and reference center, and provide useful epidemiological information to assess the impact of HPV vaccination in the future.

show abstract

“…Several clinical studies have also reported the generation of cross-protective antibodies/cross-protection by the 4vHPV or 2vHPV (i.e. antibodies to HPV 31 and 45) when administered with a three-dose schedule [54,55]. A cross-sectional study in Australia demonstrated some cross-protection only on fully vaccinated women 6 years following the introduction of the HPV vaccination programme [56].…”

Section: Gaps In the Knowledge Of Reduced Dose Hpv Schedulesmentioning

confidence: 99%